Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe NIH grant/contract note was added to the study identifiers, and the page revision was updated to v3.6.6 (replacing v3.6.5).SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5, signaling a minor update to the study record. This does not imply a substantive change to the study details.SummaryDifference0.0%

- Check31 days agoChange DetectedLung cancer and the related topics section, including MedlinePlus Genetics, were removed from the page content. This changes the list of linked topics shown but does not alter the study's design, endpoints, or enrollment information.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page now lists Lung cancer and related topics, and adds a MedlinePlus Genetics reference. The revision tag was updated from v3.6.3 to v3.6.4.SummaryDifference0.1%

- Check60 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3 on the page, indicating a small CMS or rendering update. The study details themselves appear unchanged.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page footer now displays Revision: v3.6.2, replacing v3.6.0, indicating a maintenance/version update to the page.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.